Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage.

Autor:	Leasure AC; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT., Kuohn LR; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT., Vanent KN; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT., Bevers MB; Divisions of Stroke, Cerebrovascular and Critical Care Neurology, Brigham and Women's Hospital, Boston, MA (M.B.B.)., Kimberly WT; Division of Neurocritical Care, Department of Neurology, Massachusetts General Hospital, Boston (W.T.K.)., Steiner T; Department of Neurology, Klinikum Frankfurt Höchst, Germany (T.S.).; Department of Neurology, Heidelberg University Hospital, Germany (T.S.)., Mayer SA; Departments of Neurology and Neurosurgery, New York Medical College, Westchester Medical Center Health Network, Valhalla (S.A.M.)., Matouk CC; Department of Neurosurgery (C.C.M.), Yale University School of Medicine, New Haven, CT., Sansing LH; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT., Falcone GJ; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT., Sheth KN; Department of Neurology (A.C.L., L.R.K., K.N.V., L.H.S., G.J.F., K.N.S.), Yale University School of Medicine, New Haven, CT.
Jazyk:	angličtina
Zdroj:	Stroke [Stroke] 2021 May; Vol. 52 (5), pp. 1733-1740. Date of Electronic Publication: 2021 Mar 08.
DOI:	10.1161/STROKEAHA.120.032888
Abstrakt:	Background and Objectives: IL-6 (interleukin 6) is a proinflammatory cytokine and an established biomarker in acute brain injury. We sought to determine whether admission IL-6 levels are associated with severity and functional outcome after spontaneous intracerebral hemorrhage (ICH). Methods: We performed an exploratory analysis of the recombinant activated FAST trial (Factor VII for Acute ICH). Patients with admission serum IL-6 levels were included. Regression analyses were used to assess the associations between IL-6 and 90-day modified Rankin Scale. In secondary analyses, we used linear regression to evaluate the association between IL-6 and baseline ICH and perihematomal edema volumes. Results: Of 841 enrolled patients, we included 552 (66%) with available admission IL-6 levels (mean age 64 [SD 13], female sex 203 [37%]). IL-6 was associated with poor outcome (modified Rankin Scale, 4-6; per additional 1 ng/L, odds ratio, 1.30 [95% CI, 1.04-1.63]; P =0.02) after adjustment for known predictors of outcome after ICH and treatment group. IL-6 was associated with ICH volume after adjustment for age, sex, and ICH location, and this association was modified by location (multivariable interaction, P =0.002), with a stronger association seen in lobar (β, 12.51 [95% CI, 6.47-18.55], P <0.001) versus nonlobar (β 5.32 [95% CI, 3.36-7.28], P <0.001) location. IL-6 was associated with perihematomal edema volume after adjustment for age, sex, ICH volume, and ICH location (β 1.22 [95% CI, 0.15-2.29], P =0.03). Treatment group was not associated with IL-6 levels or outcome. Conclusions: In the FAST trial population, higher admission IL-6 levels were associated with worse 90-day functional outcome and larger ICH and perihematomal edema volumes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu